天演藥業 ADAG 深 滬
等待開盤 11-05 09:30:00 美东时间
1.70
-0.090
-5.03%
華盛通- 最 高1.78
- 今 開1.71
- 成交量 9.94万股
- 最 低 1.6348
- 昨 收 1.79
- 總市值 8012.32万
- 52周最高 3.16
- 市盈率 靜 --
- 換手率 0.21%
- 52周最低 1.325
- 委 比 0.00%
- 總股本 4713.13万
- 歷史最高 31.83
- 量 比 1.99
- 振 幅 8.11%
- 歷史最低 0.90
- 每 手 1
- 風險率 0.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Adagene Says First Patient Dosed In Randomized, Open Label Phase 2 Study Of Muzastotug In Combination With Merck's Anti-PD-1 Therapy, KEYTRUDA In Patients With MSS CRC With No Liver Metastases
Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDAPatients randomized to either 10 or 20 mg/kg of muzastotug, in combination
10-31 19:02
美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
09-19 09:18
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
Adagene Inc. has amended its 2021 collaboration with Exelixis to develop an antibody-drug conjugate (ADC) targeting a solid tumor using its proprietary SAFEbody technology, enabling tumor-specific targeting with reduced side effects. Adagene is eligible for milestones and royalties, and its SAFEbody platform, designed to bind preferentially to tumor cells while masking in healthy tissues, has shown promise in clinical studies with its lead candid...
09-16 12:00
A股、H股医药板块走低，特朗普或对中国药品“动刀”，国产创新药出海影响几何？
本文来源：时代财经 作者：张羽岐 图片来源：图虫创意 9月11日，A股、H股创新药概念集体走低，百济神州（ONC.US；06160.HK；688235...
09-11 16:43
港股创新药ETF鹏华(159286)回调蓄势，机构称短期回调将砸出黄金坑机会
截至2025年9月11日09:36，国证港股通创新药指数(987018)成分股方面，诺诚健华(09969)领跌10.77%，中国生物制药(0117...
09-11 09:46
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers iSpecimen (NASDAQ:ISPC) shares increased by 80.7% to $1.35 during Tues...
09-10 01:06
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
Adagene Inc. announced that ADG126 will be highlighted in two oral presentations at the 2025 CSCO Meeting in Jinan, China. The presentations will feature updated Phase 1b/2 results of ADG126 in combination with pembrolizumab for advanced MSS colorectal cancer (CRC). Dr. Xu Ruihua and Dr. Heinz-Josef Lenz will present on September 11. ADG126, a masked anti-CTLA-4 therapy, has shown an objective response rate (ORR) of ~30% and over 80% disease cont...
09-05 13:55
Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
Adagene Inc. appoints Dr. Axel Hoos as Executive Advisor. Dr. Hoos, a pioneer in immuno-oncology and creator of the term, led the development of the first FDA-approved immune checkpoint inhibitor, YERVOY®. His expertise will guide Adagene's anti-CTLA-4 therapies, including ADG126 and ADG116, targeting metastatic microsatellite-stable (MSS) colorectal cancer. Adagene's SAFEbody technology aims to enhance efficacy and reduce toxicity in cancer immu...
09-03 13:05
Adagene to Participate in Two Investor Conferences in September
Adagene Inc. (Nasdaq: ADAG) announced that its Chief Strategy Officer, Mickael Chane-Du, will participate in investor meetings and fireside chats at two conferences in September in New York. The events include a fireside chat at the H.C. Wainwright Global Investment Conference on September 8 and another at the Morgan Stanley Global Healthcare Conference on September 10. Adagene is a biotech company focused on antibody-based therapies, with a pipe...
08-26 12:05
Adagene shares are trading higher after the company reported better-than-expected H1 adjusted EPS results.
Adagene shares are trading higher after the company reported better-than-expect...
08-13 22:41
